

- 137-1125-35.
29. Percy C, Van Holten V, Muir C, eds. *International Classification of Diseases for Oncology, Second Edition*. Geneva, Switzerland: World Health Organization, 1990.
30. Stancary M, Porter J, Caan B, et al. Energy balance and colon cancer: beyond physical activity. *Cancer Res* 1997; 57: 73-80.
31. Stancary M, Edwards S, Caan B, Kerber RA, Porter J. Response rates among control subjects in case-control studies. *Ann Epidemiol* 1995; 5: 245-9.
32. Edwards S, Stancary M, Mori M, et al. Objective system for interviewer performance evaluation for use in epidemiologic studies. *Am J Epidemiol* 1994; 140: 1020-8.
33. Micozzi MS, Albanes D, Jones Y, Chumlea WC. Correlations of body mass indices with weight, stature, and body composition in men and women in NHANES I and II. *Am J Clin Nutr* 1986; 44: 725-31.
34. McDonald A, Van Houten L, Stancary M, et al. The CARDIA dietary history: development and implementation. *Am J Diet Assoc* 1991; 91: 1104-200.
35. Liu K, Stancary M, Jacobs DR, et al. The reliability and relative validity of the CARDIA diet history. *J Chron Dis* 1994; 47: 15-27.
36. Sobush N, Jacobs DR, Blackwell W, et al. Comparison of two methods of assessing physical activity in the CARDIA study. *Am J Epidemiol* 1991; 134: 1271-45.
37. SAS Institute Inc. *SAS/AF User's Guide: Version 6, Fourth Edition*. Cary, NC: SAS Institute Inc., 1985.
38. Breslow NE, Day NE. *Statistical Methods in Cancer Research, Vol 1: The Analysis of Case-Control Studies*. Lyon, France: International Agency for Research on Cancer, 1980; IARC Sci Publ No. 32.
39. Hachow SJ, Linet MS. Agreement between questionnaire data and medical records: The evidence for accuracy of recall. *Am J Epidemiol* 1989; 129: 233-48.
40. Groshen MJ, Nomura AM, Wilkens LR, et al. Agreement between interview information and physician records on history of menopausal estrogen use. *Am J Epidemiol* 1996; 143: 815-25.
41. Kampman E, Giovannucci E, Van't Veer P, et al. Calcium, vitamin D, dairy foods, and the occurrence of colorectal adenomas among men and women in two prospective studies. *Am J Epidemiol* 1994; 139: 16-29.
42. Giovannucci E, Fegan KM, Hunter DJ, et al. Aspirin and the risk of colorectal cancer in women. *Nec Engl J Med* 1995; 333: 609-14.
43. Porter JD, Bostick RM, Grandits GA, et al. Hormone replacement therapy is associated with lower risk of adenomatous polyps of the large bowel: the Minnesota (FRI) Case-Control Study. *Cancer Epidemiol Biomark Prev* 1996; 5: 779-84.
44. McKeeuw-Beynen G. Epidemiology of colorectal cancer: reviewed: are women high-risk and/or plasma glucose associated with risk? *Cancer Epidemiol Biomark Prev* 1994; 3: 687-99.
45. McMichael AJ, Porter JD. Host factors in carcinogenesis: certain life and metabolic profiles that selectively increase the risk of proximal colon cancer. *JNCI* 1985; 75: 185-91.
46. Issa JJ, Chavarro Y, Ceballos E, Hamilton SK, Davidson NJ, Wolkstein M. Mechanism of the estrogen-increased polypoid hyperplasia and hyperplasia in human colon. *Nutriment* 1994; 7: 516-40.
47. Wyvorki DR, Golden L, Burke T. Use of menopausal estrogen and progestin/progesterone in the United States, 1982-1992. *Obstet Gynecol* 1995; 85: 6-10.

Cancer Causes and Control, 1997, 8, pp. 159-166

Tobacco and non-Hodgkin's lymphoma: combined analysis of three case-control studies (United States)

Shelia Hoar Zahn, Dennis D. Weisenburger, Frederick E. Holmes, Kenneth E. Cantor, and Aaron Blair

(Received 26 June 1996; accepted in revised form 28 October 1996)

The role of tobacco in the etiology of non-Hodgkin's lymphoma (NHL) was evaluated in a combined analysis of data from three population-based case-control studies conducted in four midwestern states of the United States: Nebraska, Iowa, Minnesota, and Kansas. Interviews were obtained from 1,177 cases (99 men, 184 women) and 1,643 controls (2,918 men, 707 women) on, if deceased, from their next-of-kin. Overall, there was no association between NHL and tobacco use (odds ratio (OR) = 1.0, 95 percent confidence interval (CI) = 0.8-1.1) or cigarette smoking (OR = 1.0, CI = 0.8-1.1). A slight negative association evident in analyses by intensity and duration of smoking was not present when interviews from proxy respondents were eliminated. There was a suggestion of a positive association between smoking and NHL among women (OR = 1.5, CI = 0.9-1.9), although there was no clear exposure-response relationship. This large case-control analysis provides no evidence that smoking is linked to the development of NHL among men. The possible role of smoking in the etiology of NHL among women needs further evaluation. *Cancer Causes and Control* 1997, 8, 159-166

Key words: Case-control studies, non-Hodgkin's lymphoma, smoking, tobacco, United States.

Introduction

Historically, non-Hodgkin's lymphoma (NHL) has not been considered a tobacco-related malignancy. Most studies have shown little or no association between NHL and smoking. [1-4] Two recent studies, [5,6] however, were more supportive of an association. A population-based case-control study of men in Iowa and Minnesota (United States) observed a 40 percent increased risk of non-

Hodgkin's lymphoma among smokers with a two- to threefold increase for high grade and unclassified non-Hodgkin's lymphoma. [5] Risk increased with duration of smoking, but not intensity. A cohort study of policyholders of the Lutheran Brotherhood Insurance Society [6] reported smokers having a twofold elevation in mortality from NHL, with an almost fourfold elevated risk among heavy smokers. No information on cell type or duration of smoking was available. In addition, the growing

Dr. Zahn, Canton, and Blair are with the Occupational Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA. Dr. Weisenburger is with the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA. Dr. Holmes is with the Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA. Address correspondence to Dr. Zahn, Occupational Epidemiology Branch, National Cancer Institute, Executive Plaza North, Room 418, 6130 Executive Boulevard, Rockville, MD 20892-7164, USA.

consensus that cigarette smoking is related causally to leukemia has suggested the need to reevaluate its role in the etiology of other hematopoietic and lymphatic malignancies, although the evidence is strongest for myeloid, not lymphoid, leukemia.¹⁷⁻¹⁹

To examine the role of tobacco in the etiology of NHL, we combined data from three population based case-control studies conducted in four midwestern US states, including the population previously reported by Brown *et al.*¹⁰ The combined dataset provided the large number of subjects required to evaluate the self-reported level of tobacco use and to focus analyses on the high risk subgroups suggested by the earlier research.

Materials and methods

The three population based case-control studies combined for this analysis were conducted in Nebraska, Iowa/Minnesota, and Kansas. Detailed descriptions of the methods for each study have been published elsewhere.^{10,11} Each study included several lymphatic and hematopoietic malignancies and, in Kansas only, soft tissue sarcoma. The studies in Iowa/Minnesota and Kansas included only White men, while the Nebraska study included both White men and White women. This report will evaluate NHL among White men and women.

Cases

In Nebraska, all cases of NHL among White men and women, age 21 years or older, residing in the 66 counties

of eastern Nebraska, and diagnosed between 1 July 1983 and 30 June 1986, were identified through the Nebraska Lymphoma Study Group and area hospitals (*n* = 227 men, 214 women) (Table 1). In the Iowa/Minnesota study, all newly diagnosed cases of NHL among White men, aged 50 years or older, were ascertained from Iowa State Health Registry records and a special surveillance of Minnesota hospital and pathology laboratory records (*n* = 780). The diagnosis period for eligibility was March 1981 through October 1983 in Iowa, and October 1980 through September 1982 in Minnesota. In Minnesota, cases who resided in the cities of Minneapolis, St. Paul, Duluth, or Rochester at the time of diagnosis were excluded because agricultural exposures were the primary focus of the original investigations. In Kansas, all cases of NHL among White men, aged 21 years or older, diagnosed from 1979 through 1981, were identified through the University of Kansas Cancer Data Service, a registry covering the state of Kansas. A random sample of 200 men was drawn from the 297 NHL cases diagnosed in Kansas during the eligible time period.

Tumor tissue from the cases was reviewed by expert pathologists and classified according to the Working Formulation.²⁰ Analysis of follicular (Working Formulation categories II (1), diffuse (Working Formulation categories I (1), small lymphocytic (Working Formulation category A), and other (Working Formulation categories II (2) and miscellaneous) NHL are presented. Only histologically confirmed cases were included. The number of confirmed cases was 426 (220 men, 206 women) in Nebraska and 172 in Kansas. In Iowa/Minnesota, the

Table 1. Number of non-Hodgkin's lymphoma cases and controls, response rates, and study methods in the case-control studies in Nebraska, Kansas, and Iowa/Minnesota

	Nebraska		Kansas		Iowa/Minnesota	
	Men	Women	Men	Women	Men	Women
Cases identified	227	214	200	780	780	780
Historically confirmed	220	206	172	—	—	—
Interviewed	201	184	170	622	622	622
Interview response rate	91%	86%	96%	88%	88%	88%
Controls identified	831	824	1,005	1,543	1,543	1,543
Interviewed	725	707	948	1,245	1,245	1,245
Interview response rate	87%	86%	94%	81%	81%	81%
Overall control response rate ^a	85%	84%	90%	78%	78%	78%

^a Pathology review occurred after the interviews were conducted. Cases who were not interviewed did not undergo pathology review.

^b The 96 percent response rate was based on 170 interviews out of 172 confirmed non-Hodgkin's lymphoma cases initially diagnosed as non-Hodgkin's lymphoma and the non-Hodgkin's lymphoma cases initially diagnosed as other cancer types in the study (e.g., Hodgkin's disease).

^c Overall control response rates account for the response rates in the initial household census and the interview response rates.

pathology review occurred after the interviews were obtained from cases. Because cases who were not interviewed did not undergo pathology review, the total number of eligible, histologically confirmed cases cannot be determined.

Controls

Controls were selected randomly from the same geographic areas as cases, with frequency matching by race, gender, five-year age group, and vital status at the time of the interview. The living cases were age 65, controls of the deceased were age 65 or older. Controls were selected by two-stage random-digit dialing (RDD).²¹ For living cases aged 65 or older, controls were selected from the Health Care Financing Administration (Medicare) records. For deceased cases, controls were selected from state mortality files with additional matching for year of death. Persons with a cause of death of a malignancy under study, or in Kansas and Nebraska, a malignancy of an ill-defined site, homicide, suicide, or legal intervention were excluded. A total of 4,203 controls (Nebraska: 831 men, 824 women; Kansas: 1,005; Iowa/Minnesota: 1,543) were identified.

Interviews

Interviews were conducted with the subjects, or their next of kin if the subjects were deceased or uncontacted. The interviews were done by telephone in Nebraska and Kansas and in person in Iowa/Minnesota. In Nebraska, 385 cases (201 men, 184 women) and 1,412 controls (725 men, 707 women) were interviewed, yielding interview response rates of 91 percent for male cases, 89 percent for female cases, 87 percent for male controls, and 86 percent for female controls. The overall response rate for controls, which accounted for the 91 percent response rate in the household census phase of the RDD procedure, was 85 percent for men and 84 percent for women. In Kansas, 170 cases and 948 controls were interviewed, yielding interview response rates of 96 percent and 94 percent, respectively. The RDD household census had a 92.3 percent response rate which made the overall control response rate 90 percent. In Iowa/Minnesota, 780 presumptive NHL cases were ascertained and 694 (89 percent) were interviewed. After pathology review of the interviewed cases, 622 were confirmed as NHL. Interviews also were obtained from 1,245 controls (81 percent) in Iowa/Minnesota. The overall response rate for controls, accounting for the 87.5 percent household census response rate, was 78 percent. Combining the three studies, interviews were obtained from 1,177 eligible cases (993 men, 184 women) and 3,625 controls (2,918 men, 707 women). Fourteen male controls were excluded from the analyses in this report because of missing data.

In each study, the interviews contained detailed questions on tobacco use including: the use of cigarettes;

age or calendar year the person started smoking; the number of years of smoking (Kansas) or the age or calendar year the person stopped smoking (Nebraska and Iowa/Minnesota); average number of cigarettes per day; use of cigars or pipes; and use of smokeless tobacco. Because not all of the studies collected detailed information on intensity and duration of non-cigarette tobacco products, those data will not be presented. The interviews also included other potential risk factors for non-Hodgkin's lymphoma, such as a family history of cancer, employment as a farmer, pesticide use, occupational exposures, and medical conditions, with some variation across the three studies.

Risk measurement

The measure of association was the odds ratio (OR). Combining the subjects from the three studies, risk estimates for tobacco use were adjusted for age (20-44, 45-64, 65-74, 75+), gender, and state (Nebraska, Kansas, Iowa, Minnesota) by stratification. The source of the interview, i.e., study subjects themselves or proxy respondents, was found to be a negative confounder in these data and was added as a stratification factor. Adjustment for ever having lived or worked on a farm did not change risk estimates and is not presented in this report. Maximum likelihood estimates of the overall risk and 95 percent confidence intervals (CI) were computed by Gail's method.²² For duration and intensity-response relationships, significance was assessed by means of Mantel's one-tailed linear trend test.²³

Results

Table 2 presents the ORs for NHL by characteristics of tobacco use for all subjects combined and by respondent type. Overall, there was no association between NHL and any tobacco use or cigarette smoking. Risk appeared to decrease slightly with increasing intensity and duration of smoking, primarily due to the negative associations among subjects represented by proxy respondents. Analyses based on living subjects alone showed an excess of borderline significance among current smokers, but no exposure-response gradients were observed.

The role of smoking in the development of NHL appeared to differ by gender (Table 3). While there appeared to be little or no association in men, particularly among subject respondents, NHL was associated with smoking among women. Among the female subject respondent smokers, NHL was increased about twofold, however, the exposure-response gradients, although statistically significant, were inconsistent and generally diminished in the highest category. The ORs were similar for exposure-response gradients among ex- and current smokers (data not shown).

Table 2. Number of non-Hodgkin's lymphoma (NHL) cases and controls and odds ratios (OR) for tobacco use by respondent type in Eastern Nebraska, Kansas, Iowa, and Minnesota.

Tobacco use	Total				Direct subject respondents				Proxy respondents			
	NHL	Controls	OR	(CI) ^a	NHL	Controls	OR	(CI) ^b	NHL	Controls	OR	(CI) ^b
No tobacco use	356	1,179	—	—	221	753	—	—	135	426	—	—
Ever used tobacco	820	2,424	1.0	(0.8-1.1)	516	1,330	1.1	(0.9-1.4)	304	1,084	0.7	(0.6-1.0)
Unknown	1	8	—	—	0	3	—	—	1	5	—	—
Cigarette smokers	726	2,164	1.0	(0.8-1.1)	467	1,203	1.1	(0.9-1.4)	256	961	0.7	(0.6-1.0)
Ex-smokers	371	1,134	0.9	(0.7-1.1)	257	712	1.0	(0.8-1.3)	114	422	0.7	(0.5-1.0)
Current	308	850	1.1	(0.9-1.3)	203	476	1.3	(1.0-1.6)	105	374	0.8	(0.5-1.1)
Unknown ^c	47	180	—	—	7	15	—	—	40	165	—	—
Cigarettes per day												
1-9	98	253	1.1	(0.8-1.4)	58	157	1.0	(0.7-1.5)	41	96	1.2	(0.7-1.8)
10-19	136	353	1.1	(0.9-1.5)	83	206	1.3	(1.0-1.6)	43	147	0.8	(0.5-1.3)
20	251	753	0.9	(0.8-1.2)	176	451	1.1	(0.9-1.5)	73	302	0.6	(0.4-0.9)
21+	210	693	0.8	(0.6-1.0)	136	377	0.9	(0.7-1.2)	75	316	0.6	(0.4-0.9)
Unknown	30	112	—	—	3	12	—	—	27	100	—	—
Chi, P-value for trend ^d			-0.8, 0.04				0.3, 0.4				-3.6, <0.0001	
Years smoked												
1-10	79	230	1.2	(0.8-1.6)	56	178	1.1	(0.7-1.6)	23	52	1.4	(0.8-2.5)
11-20	101	284	1.1	(0.8-1.5)	69	211	1.0	(0.7-1.5)	32	83	1.2	(0.7-2.1)
21-30	120	316	1.1	(0.8-1.4)	85	218	1.0	(0.7-1.4)	35	97	1.2	(0.7-2.0)
31-40	136	402	0.8	(0.6-1.1)	97	231	1.1	(0.8-1.5)	39	171	0.5	(0.3-0.8)
41+	244	751	0.9	(0.7-1.1)	161	440	1.1	(0.8-1.5)	91	402	0.6	(0.4-0.9)
Unknown	46	171	—	—	7	15	—	—	39	156	—	—
Chi, P-value for trend ^d			-1.3, 0.1				1.1, 0.1				-3.6, <0.0001	
Pack-years												
< 15	159	456	1.1	(0.8-1.4)	108	321	1.1	(0.8-1.4)	51	135	1.1	(0.7-1.7)
15 - < 35	186	511	1.1	(0.8-1.3)	139	343	1.2	(0.9-1.6)	47	168	0.8	(0.5-1.2)
35 - < 55	169	474	0.9	(0.7-1.1)	123	293	1.0	(0.8-1.4)	46	181	0.6	(0.4-1.0)
55 - 155	148	497	0.8	(0.6-1.0)	89	222	0.9	(0.7-1.3)	59	275	0.5	(0.3-0.8)
Chi, P-value for trend			-1.7, 0.04				0.6, 0.3				-3.6, <0.0001	

^a Odds ratio (95 percent confidence interval) adjusted for age, gender, state, and respondent type, compared with nonusers of tobacco.

^b Odds ratio (95 percent confidence interval) adjusted for age, gender, and state, compared to nonusers of tobacco.

^c Some smokers could not be classified as ex- or current smokers because of missing values for either age started or years of smoking, variables used to impute current smoking status in the Kansas study.

^d Trend tests do not include the unknown category.

Among men, there was no evidence for a role of tobacco in follicular lymphoma (OR = 1.0, CI = 0.7-1.3) (Table 4). Smokers had a slightly decreased risk of diffuse lymphoma (OR = 0.8, CI = 0.6-1.0) and small lymphocytic lymphoma (OR = 0.7, CI = 0.5-1.1), and an increased risk of the remaining types of NHL (OR = 1.4, CI = 1.0-2.1). No consistent exposure-response gradients were observed (data not shown). These relationships were not changed when analyses were restricted to interviews supplied directly by subjects.

Among women, tobacco users had nonsignificant increased risks of follicular, diffuse, and small lymphocytic lymphoma (Table 4). Analyses of detailed smoking characteristics were limited by small numbers of exposed

female cases, but showed greater risks for these three histologic types of NHL among current smokers than among ex-smokers. Risk for follicular and, to a greater extent, small lymphocytic lymphoma appeared to increase with years smoked ($P = 0.02$), based on small numbers (data not shown). Female smokers generally had no greater risk of other histologic types of NHL than non-smokers.

Other forms of tobacco showed no association with NHL, whether used alone or in combination with each other. Persons who ever smoked pipes or cigars had an OR of 0.9 (CI = 0.7-1.1) for NHL. Smokeless tobacco users had an OR of 1.0 (CI = 0.7-1.2). Among persons who used only one type of tobacco, the pipe or cigar

Table 3. Number of non-Hodgkin's lymphoma (NHL) cases and controls and odds ratios (OR) for tobacco use by gender and respondent type in Eastern Nebraska, Kansas, Iowa, and Minnesota.

Tobacco use	Men								Women							
	Total respondents ^a				Direct subject respondents				Total respondents ^a				Direct subject respondents			
	NHL	Controls	OR	(CI) ^b	NHL	Controls	OR	(CI)	NHL	Controls	OR	(CI)	NHL	Controls	OR	(CI)
No tobacco use	240	685	—	—	154	434	—	—	116	494	—	—	67	319	—	—
Ever used tobacco	752	2,216	0.9	(0.7-1.1)	1,203	1,203	1.0	(0.8-1.2)	68	206	1.3	(0.9-1.9)	50	127	1.9	(1.2-3.0)
Unknown	1	3	—	—	0	0	—	—	0	5	—	—	0	3	—	—
Cigarette smokers	658	1,957	0.9	(0.7-1.1)	417	1,076	1.0	(0.8-1.2)	68	207	1.3	(0.9-1.9)	50	127	1.9	(1.2-3.0)
Ex-smokers	350	1,054	0.9	(0.7-1.1)	238	660	0.9	(0.7-1.2)	21	80	1.0	(0.6-1.9)	19	52	1.7	(0.9-3.3)
Current	269	746	1.0	(0.8-1.2)	175	402	1.1	(0.9-1.5)	39	104	1.5	(0.9-2.4)	28	74	1.9	(1.1-3.3)
Unknown ^c	39	157	—	—	4	14	—	—	8	23	—	—	3	1	—	—
Cigarettes per day																
1-9	86	194	1.1	(0.8-1.5)	48	114	1.0	(0.7-1.6)	13	59	0.9	(0.5-1.9)	10	43	1.1	(0.5-2.5)
10-19	115	318	1.0	(0.7-1.3)	80	182	1.2	(0.8-1.7)	21	35	2.5	(1.3-4.8)	13	24	2.9	(1.3-6.5)
20	229	690	0.9	(0.7-1.1)	157	414	1.0	(0.7-1.3)	22	63	1.3	(0.7-2.3)	21	37	2.7	(1.4-5.3)
21+	203	652	0.8	(0.6-1.0)	130	356	0.9	(0.7-1.2)	7	41	0.5	(0.2-1.3)	5	21	1.1	(0.3-3.4)
Unknown	25	103	—	—	2	10	—	—	5	9	—	—	2	2	—	—
Chi, P-value for trend ^d			-2.2; 0.02				-0.7; 0.3				0.7; 0.3				2.9; 0.002	
Years smoked																
1-10	73	191	1.2	(0.8-1.8)	53	149	1.2	(0.8-1.7)	6	39	0.8	(0.3-2.0)	3	29	0.6	(0.1-2.4)
11-20	93	270	1.1	(0.8-1.4)	62	192	1.0	(0.7-1.4)	8	24	1.5	(0.5-3.8)	7	19	1.8	(0.6-5.0)
21-30	113	287	1.1	(0.8-1.4)	79	198	1.0	(0.7-1.4)	7	29	1.0	(0.4-2.6)	6	21	1.5	(0.5-4.2)
31-40	118	371	0.7	(0.6-1.0)	80	212	0.9	(0.6-1.2)	18	31	1.9	(1.0-3.9)	17	19	3.7	(1.7-8.4)
41+	223	690	0.8	(0.7-1.0)	139	311	1.0	(0.8-1.4)	21	61	1.2	(0.7-2.1)	14	38	1.7	(0.8-3.4)
Unknown	38	148	—	—	4	14	—	—	8	23	—	—	3	1	—	—
Chi, P-value for trend ^d			-2.2; 0.02				-0.1; 0.4				1.7; 0.04				3.1; 0.001	
Pack-years																
> 15	144	384	1.1	(0.8-1.4)	96	265	1.0	(0.8-1.4)	15	72	0.9	(0.5-1.8)	12	56	1.1	(0.5-2.4)
15 - < 35	163	460	1.0	(0.7-1.2)	120	305	1.0	(0.8-1.4)	23	51	1.6	(1.0-3.3)	19	38	2.5	(1.3-4.8)
35 - < 55	154	439	0.8	(0.6-1.1)	110	273	0.9	(0.7-1.2)	15	35	1.5	(0.7-3.0)	13	20	2.9	(1.2-6.9)
55 - 155	143	475	0.8	(0.6-1.0)	86	212	0.9	(0.7-1.3)	5	22	0.6	(0.2-1.9)	3	10	1.3	(0.3-5.2)
Chi, P-value for trend			-2.2; 0.01				-0.5; 0.3				1.1; 0.1				3.0; 0.001	

^a Total respondents includes subject respondents and proxy respondents.

^b Odds ratio (95 percent confidence interval) adjusted for age, state, and respondent type, compared with non-tobacco users.

^c Some smokers could not be classified as ex- or current smokers because of missing values for either age started or years of smoking, variables used to impute current smoking status in the Kansas study.

^d Trend tests do not include the unknown category.

Table 4. Number of non-Hodgkin's lymphoma (NHL) cases and controls and odds ratios (OR) for tobacco use by histologic type^a and gender in Eastern Nebraska, Kansas, Iowa, and Minnesota

Tobacco use	Follicular		Diffuse		Small lymphocytic		Other	
	NHL	Controls	OR	(CI) ^b	NHL	Controls	OR	(CI)
Men								
No tobacco use	685	89	—	—	32	—	37	—
Ever tobacco use	2,216	216	1.0	(0.7-1.3)	268	0.8	(0.6-1.0)	188
Unknown	3	0	—	—	1	—	0	—
Cigarette smokers	1,957	191	1.0	(0.7-1.3)	237	0.8	(0.6-1.0)	169
Ex-smokers	1,004	88	0.9	(0.6-1.2)	134	0.8	(0.6-1.1)	80
Current	746	88	1.1	(0.8-1.7)	88	0.8	(0.5-1.1)	71
Unknown ^c	157	4	—	—	15	—	18	—
Women								
No tobacco use	494	36	—	—	4	—	36	—
Ever tobacco use	208	20	1.3	(0.7-2.5)	27	1.6	(0.9-2.8)	16
Unknown	5	0	—	—	0	—	0	—
Cigarette smokers	207	20	1.3	(0.7-2.5)	27	1.6	(0.9-2.8)	16
Ex-smokers	80	6	0.9	(0.3-2.3)	7	1.1	(0.4-2.8)	6
Current	104	12	1.4	(0.6-3.0)	16	1.8	(0.8-3.8)	8
Unknown ^c	23	2	—	—	4	—	2	—

^a Histology: follicular (Working Formulation B-1), diffuse (Working Formulation E-1), small lymphocytic (Working Formulation A), other (Working Formulation H-1) and miscellaneous.

^b Odds ratio (95 percent confidence interval) adjusted for age, site, and respondent type, compared to nonusers of tobacco.

^c Some smokers could not be classified as ex or current smokers because of missing values for either age started or years of smoking; variables used to impute current smoking status in the Kansas study.

Family history of cancer did not significantly modify the risk of NHL associated with smoking.

Discussion

This combined analysis of data from three population-based case-control studies was based on approximately 1,200 cases and 3,600 controls. A total of 726 cases and 2,164 controls smoked cigarettes, making this study far larger than any single study previously published on NHL and tobacco use. Overall, there was no association with cigarette smoking or use of other forms of tobacco. A slight negative association evident in the analyses by intensity and duration of smoking was not present when analyses were restricted to information obtained directly from living subjects. Proxy respondents for deceased cases and matched deceased controls showed significantly decreased risks of NHL, probably due to the inclusion of controls with smoking related causes of death.¹¹ While it would be possible to exclude known smoking related causes of death from the deceased controls for reanalysis,

level based on small numbers of cases. Additional data on smoking and NHL among women are needed.

If smoking were related causally to NHL among women, the increase in smoking among women in recent decades⁴⁰ might explain some of the 57 percent increase among women in the incidence of NHL over the past 20 years.⁴¹ Most other known and postulated causes of NHL, such as human immunodeficiency virus, pesticides, and solvents, are more prevalent among men than women.⁴² The agents responsible for the rising incidence of NHL might differ among men and women. Cigarette smoking and other factors, such as use of hair coloring products,⁴³ may be responsible for the rise in women, but play little or no role among men.

This large case-control study provides strong evidence that smoking has little or no effect on the development of NHL among men. However, the possible role of smoking in the etiology of NHL among women needs further evaluation to determine if a gender-specific response may occur.

References

1. Doll R. Mortality in relation to smoking: 20 years' observation on male British doctors. *Br Med J* 1976; 2: 1525-36.
2. Williams RH, Hyatt JH. Association of cancer sites with tobacco and alcohol consumption and socioeconomic status of patients: interview study from the Third National Cancer Survey. *JNCI* 1977; 58: 525-47.
3. Peto J, Peto RC, Smith J, et al. The risk of lung cancer in relation to smoking: a case-control study of adult cases of lung cancer, lymphomas, and leukemias: brief communication. *JNCI* 1978; 60: 89-92.
4. Rigotti E, Murray J. Smoking and causes of death among US veterans: 16 years of observation. *Public Health Rep* 1980; 95: 213-22.
5. Heston SK, Blair A, Holmes JT, et al. Agricultural herbicide use and risk of lymphoma and soft tissue sarcoma. *JAMA* 1986; 256: 1141-7.
6. Cartwright KA, McKinney PA, O'Brien C, et al. Non-Hodgkin's lymphoma: case control epidemiologic study in Yorkshire. *Leukemia Res* 1988; 12: 81-8.
7. Franceschi S, Serraino D, Bidoli E, et al. The epidemiology of non-Hodgkin's lymphoma in the north-east of Italy: a hospital based case-control study. *Leukemia Res* 1989; 13: 463-72.
8. Tivani A, Negri E, Franceschi S, Serraino D, La Vecchia C. Smoking habits and non-Hodgkin's lymphoma: a case-control study in northern Italy. *Prev Med* 1994; 23: 447-52.
9. Simoncini J, Krawski J, Franco E, Kasperian M. Association between cigarette smoking and each of 21 types of cancer: a multi-site case-control study. *Int J Epidemiol* 1995; 24: 504-14.
10. Brown LM, Everett GJ, Gibson R, Bunimann JF, Selman LM, Blair A. Smoking and risk of non-Hodgkin's lymphoma and multiple myeloma. *Cancer Causes Control* 1992; 3: 49-55.
11. Linn MS, McLaughlin JK, Hsing AW, et al. Is cigarette smoking a risk factor for non-Hodgkin's lymphoma or multiple myeloma? Results from the Lutheran Brother-
12. Good Cohort Study. *Leukemia Res* 1992; 16: 621-4.
13. Kralin LJ, Rigotti E. Leukemia and smoking habits among United States veterans. *Br Med J* 1988; 297: 657-9.
14. Sandler D, Shore D, Anderson J, et al. Cigarette smoking and risk of acute leukemia: associations with morphology and cytogenetic abnormalities in bone marrow. *JNCI* 1993; 85: 1994-2003.
15. Doll R, Peto R, Wheatley K, Gray R, Sutherland I. Mortality in relation to smoking: 40 years' observations on male British doctors. *Br Med J* 1994; 309: 901-11.
16. McLaughlin JK, Hrubec Z, Blot WJ, Fraumeni JF Jr. Smoking and cancer mortality among US veterans: a 26 year follow-up. *Int J Cancer* 1995; 60: 190-3.
17. Bain HJ. Does cigarette smoking cause leukemia? *Smoking Related* 1995; 5: 115-22.
18. Zahm SH, Weisenburger DJ, Babbitt PA, et al. A case-control study of non-Hodgkin's lymphoma and the use of hair coloring products and (2,4-D) in eastern Nebraska. *Epidemiology* 1990; 1: 349-56.
19. Cantor KP, Blair A, Everett G, et al. Pesticides and other agricultural risk factors for non-Hodgkin's lymphoma among men in Iowa and Minnesota. *Cancer Res* 1992; 52: 2447-55.
20. Brown LM, Linn MS, Blair A, et al. Familial cancers associated with subtypes of leukemia and non-Hodgkin's lymphoma. *Leukemia Res* 1991; 15: 305-14.
21. Zahm SH, Blair A, Holmes JT, Brown LM, Kralin MJ. A case-control study of soft tissue sarcoma. *Am J Epidemiol* 1989; 130: 662-74.
22. Zahm SH, Blair A, Holmes JT, Brown LM, Kralin MJ, Fraumeni JF Jr. A case-control study of soft tissue sarcoma. *Am J Epidemiol* 1989; 130: 662-74.
23. Zahm SH, Weisenburger DJ, Babbitt PA, Sael RC, Vaughn JB, Blair A. Use of hair coloring products and the risk of lymphoma, multiple myeloma, and chronic lymphocytic leukemia. *Am J Public Health* 1992; 82: 990-7.
24. Zahm SH, Weisenburger DJ, Cantor KP, Holmes JT, Blair A. Role of the herbicide atrazine in the development of non-Hodgkin's lymphoma. *Scand J Work Environ Health* 1993; 19: 108-14.
25. Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas: Summary and description of a Working Formulation for clinical usage. *Cancer* 1982; 49: 212-35.
26. Dick F, Van Lier S, Banks P, et al. Use of the Working Formulation for non-Hodgkin's lymphoma in epidemiologic studies: Agreement between reported diagnoses and a panel of experienced pathologists. *JNCI* 1987; 78: 1137-44.
27. Dick FR, Van Lier SF, McKen K, Everett GD, Blair A. Nonconcordance in abstracted diagnoses of non-Hodgkin's lymphoma. *JNCI* 1987; 78: 675-8.
28. Waldenborg J. Sampling methods for random digit dialing. *J Am Stat Assoc* 1978; 73: 40-6.
29. Gart J. Point and interval estimation of the common odds ratio in the combination of 2 x 2 tables with fixed marginals. *Biometrika* 1970; 57: 471-5.
30. Mantel N. Chi-square test with 1 degree of freedom, extension of the Mantel-Haenszel procedure. *Am Stat Assoc* 1965; 58: 690-700.
31. McLaughlin JK, Blot WJ, Miettinen ES, Mandel JS. Problems

- in the use of dead controls in case-control studies. II. Effect of excluding certain causes of death. *Am J Epidemiol* 1985; 122: 485-94.
32. Reich HA, Howe GR, Jain M, Burch JD, Holowaty EJ, Miller AB. Are female smokers at higher risk for lung cancer than male smokers? A case-control analysis by histologic type. *Am J Epidemiol* 1993; 138: 281-93.
33. Osann KE, Anton-Culver IL, Kutsaki T, Taylor T. Sex difference in lung cancer risk associated with cigarette smoking. *Am J Cancer* 1993; 54: 44-8.
34. Zang EA, Wynder EL. Differences in lung cancer risk between men and women: examination of the evidence. *JNCI* 1996; 88: 183-92.
35. Brown LM, Gibson R, Blair A, et al. Smoking and risk of leukemia. *Am J Epidemiol* 1992; 135: 763-8.
36. Cantor K, Ichihashi J, Schwartz D. Smoking and leukocyte counts: Results of an epidemiologic survey. *Cancer* 1971; 26: 632-3.
37. Friedman GD, Siegelman AB, Selzer CG, Friedman R, Cohen ME. Smoking habits and the leukocyte count. *Arch Environ Health* 1973; 28: 137-43.
38. Hickey P, Prendergast D, Edwards A. Effects of cigarette smoking on the immune system: Follow up studies in normal subjects after cessation of smoking. *Med J Aust* 1985; 143: 425-9.
39. Tollerud DJ, Clark JW, Brown LM, et al. The effects of cigarette smoking on T cell subsets: a population based survey of healthy Caucasians. *Am Rev Respir Dis* 1989; 139: 1446-51.
40. Tollerud DJ, Clark JW, Brown LM, et al. Association of cigarette smoking with decreased numbers of circulating natural killer cells. *Am Rev Respir Dis* 1989; 139: 194-8.
41. Filipovich AI, Mathur A, Kama D, Shapiro RS. Primary immunodeficiencies: genetic risk factors for lymphoma. *Cancer Res* 1992; 52(Suppl): 5465S-7S.
42. Kihnel I. Immunosuppressive therapy and acquired immunological disorders. *Cancer Res* 1992; 52(Suppl): 5474S-6S.
43. Burns DM, Lee I, Shen Z, et al. Cigarette smoking behavior in the United States: In: *Changes in Cigarette Related Disease Risks and Their Implication for Prevention and Control* (USA). National Cancer Institute; NIH Pub. No. 97-4213 (in press).
44. Kuo I, Ait, Miller BA, Hankey BT, Kosary CL, Lomas A, Edwards BK, eds. *Vital and Mortality Statistics, 1991: Tables and Graphs*. Bethesda, MD (USA): National Cancer Institute, 1994. NIH Pub. No. 94-2789.
45. Hargreave J, Deves SS. Quantification of the impact of known risk factors on time trends in non-Hodgkin's lymphoma incidence. *Cancer Res* 1992; 52(Suppl): 5566S-9S.
46. Zahm SH, Blair A. Pesticides and non-Hodgkin's lymphoma. *Cancer Res* 1992; 52(Suppl): 5485S-8S.
47. Pearce N. Increasing incidence of non-Hodgkin's lymphoma: occupational and environmental factors. *Cancer Res* 1992; 52(Suppl): 5496S-500S.
48. Zahm SH, Blair A, Freeman JE Jr. Hair coloring product use: safe or still suspect? *JNCI* 1994; 86: 941-3.

Childhood leukemia and electromagnetic fields: results of a population-based case-control study in Germany

Jörg Michaelis, Joachim Schüz, Rolf Meinert, Michael Mengers, Jan-Peter Grigat, Peter Kaatsch, Uwe Kaltsch, Anke Meisner, Andreas Stamm, Karl Brinkmann, and Hermann Kärner

(Received 9 July 1996; accepted in revised form 21 October 1996)

The investigation of an association between increased exposure to residential extremely-low frequency electromagnetic fields (ELF-EMF) and childhood leukemia was part of a population-based case-control study carried out between 1992 and 1995 in the northwestern part of Germany. A total of 129 children with leukemia and 328 controls participated in the EMF-study. Exposure assessment comprised measurements of the magnetic field over 24 hours in the child's bedroom at the residence where the child had been living for the longest period before the date of diagnosis, and spot measurements at all residences where the child had been living for more than one year. The median of the 24h-measurement in the child's bedroom was regarded as the most valid exposure variable. For children exposed to more than 0.2 µT, an elevated but not significant odds ratio (OR) was observed (OR = 3.2, 95 percent confidence interval = 0.7-14.9). These figures are based on only four leukemia cases and three controls since only 1.5 percent of the study population was classified as highly exposed. Exploratory analyses revealed ORs that were not statistically significantly increased for other characteristics of the magnetic field at varying cut-points. The results are comparable with those from other studies. Although not statistically significant, they may indicate a positive association between EMF and childhood leukemia. *Cancer Causes and Control* 1997, 8, 167-174

Key words: Case control study, child, electromagnetic fields, Germany, leukemia.

Introduction

Since Wertheimer and Leeper¹ published the results of an epidemiologic study on electrical wiring configurations and childhood cancer, several studies²⁻⁹ have been carried out examining the hypothesis that there is an association between residential extremely-low-frequency electro-

magnetic fields (ELF-EMF) and cancer in children. There are two main reasons for carrying out another study on residential EMF and childhood cancer. First, a number of factors prevent strong conclusions from being drawn concerning the possible effects of magnetic fields on either

Authors are with the Institut für Medizinische Statistik und Dokumentation, Johannes-Gutenberg-University, Mainz, Germany (Dr. Michaelis, Mr. Schüz, Mr. Meinert, Dr. Kaatsch, Ms. Kaltsch, Ms. Meisner); the Forschungszentrum: Elektromagnetische Verträglichkeit biologischer Systeme, Technical University of Braunschweig, Germany (Mr. Mengers, Mr. Grigat, Dr. Stamm, Dr. Brinkmann); the Institut für Epidemiologie, Biostatistik, Technical University of Braunschweig, Germany (Dr. Kärner). Address correspondence to Dr. Michaelis, Institut für Medizinische Statistik und Dokumentation, Langenbeckstr. 1, 55101 Mainz, Germany. This study was funded partially by the Ministry of Health of Lower Saxony.